含钆MR对比剂与肾源性系统性纤维化的关系
被引量:7
The relationship of nephrogenic systemic fibrosis with exposure to gadolinium contrast agents
摘要
肾源性系统性纤维化(Nephrogenicsy stemic fibrosis,NSF)是近年才发现的一种仅发生于肾病患者的全身性疾病。NSF最初于1997年在美国南加利福尼亚的。肾移植中心发现,于2000年由Cowper等报道,称为“透析引起的硬化性黏液水肿样皮肤病”,2001年又对其临床和组织学特点进行了描述,将其命名为肾源性纤维化性皮肤病(NFD),
出处
《中国临床医学影像杂志》
CAS
北大核心
2009年第1期53-54,共2页
Journal of China Clinic Medical Imaging
参考文献11
-
1Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema like cutaneous diseases in renal-dialysis patients [J]. Lancet, 2000, 356: 1000-1001.
-
2Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy(Review)[J]. Am J Dermatopathol, 2001, 23: 383-393.
-
3Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy(Review)[J]. Am J Kidney Dis, 2005, 46: 763-765.
-
4Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? [J]. Nephrol Dial Transplant, 2006, 21: 1104-1108.
-
5Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging [J]. J Am Soc Nephrol, 2006, 17: 2359-2362.
-
6High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis[J]. J Am Acad Dermatol, 2007, 56: 21-26.
-
7Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy [J]. J Am Acad Dermatol, 2007, 56: 27-30.
-
8Centers for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents: St.Louis, Missouri, 2002-2006[J]. MMWR, 2007, 56: 137-141.
-
9Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation[J]. Radiology, 2007, 243: 148-157.
-
10Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concermed[J]. AJR, 2007, 188: 586-592.
同被引文献57
-
1王翠艳,赵斌,王光彬,张增芳,邱秀玲.三维增强MR血管成像在周围型动脉闭塞症分级中的应用价值[J].中华放射学杂志,2007,41(6):598-601. 被引量:11
-
2Reed PS,Dixon SR,Boura JA,et al.Comparison of the usefulness of Gadodiamide and iodine mixture versus iodinated contrast alone for prevention of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography.Am J Cardiol,2007,100:1090-1093.
-
3Sam AD,Morasch SD,Collins J,et al.Safety and gadolinium contrast angiography in patients with chronic renal insufficiency.J Vasc Surg,2003,38:313-318.
-
4Runge VM.Safety of approved MR contrast media for intravenous injection.J Magn Reson Imaging,2000,12:205-213.
-
5Grobner T.Gadolinium:a special trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis.Nephrol Dial Transplant,2006,21:1104-1108.
-
6Marckmann P,Skov L,Rossen K,et al.Nephrogenic systemic fibrosis:suspected causative role of gadodiamide used for contrastenhanced magnetic resonance imagping.J Am Soc Nephrol,2006,17:2359-2362.
-
7High WA,Ayers RA,Chandler J,et al.Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.J Am Acad Dermatol,2007,56:21-26.
-
8Bryant BJ,Im K,Broome DR.Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.Clin Radiol,2009,64:706-713.
-
9Levey AS,Coresh J,Balk E,et al.National Kidney Foundation practice guidelines for chronic kidney disease:evaluation,classification,and stratification.Ann Intern Med,2003:137-147.
-
10Ma YC,Zou L,Chen JH,et al.Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease.J Am Soc Nephrol,2006,17:2937-2944.
引证文献7
-
1朱飞鹏,张龙江,卢光明.肾源性系统性纤维化与磁共振含钆对比剂[J].放射学实践,2010,25(2):219-221. 被引量:10
-
2罗健,刘婧,王霄英,杨学东,蒋学祥.静脉注射对比剂钆喷替酸葡甲胺对肾功能正常及轻、中度异常者近期血清肌酐值的影响[J].中华放射学杂志,2010,44(12):1253-1257. 被引量:10
-
3范影,谢玉海,张涤非,赵雷,史晓飞,曹莉,哈传传.低剂量对比剂在头颈部3D CE-MRA中的应用研究[J].中国医药指南,2012,10(29):7-9. 被引量:1
-
4倪政欣,邱光,周建华.T2WI、T2WI+FS、DWI及增强T1WI+FS序列在肛瘘诊断中的价值对比[J].医药前沿,2018,8(34):101-103. 被引量:1
-
5谢玉海,范影,钱银锋,李曼曼,赵雷,史晓飞,曹莉,哈传传.小腿加压下肢动脉1.5T三维对比增强MRA对比剂剂量的对比研究[J].中国CT和MRI杂志,2014,12(6):95-98. 被引量:2
-
6张玲,李大鹏.低剂量对比剂在下肢动脉疾病3D CE-MRA中的应用[J].医疗卫生装备,2017,38(4):74-77. 被引量:6
-
7刘曦娇,李峥艳,张薇薇,刁乙珂,付宇,许乙凯,王劲,任静,沈文,宋彬.钆布醇在腹部增强磁共振动脉血管成像中的应用价值:一项前瞻性、多中心研究[J].中国普外基础与临床杂志,2020,27(5):615-618. 被引量:2
二级引证文献32
-
1宋立群,曲健.钆造影剂与肾源性系统性纤维化[J].中国中西医结合肾病杂志,2011,12(10):847-849. 被引量:1
-
2范影,谢玉海,张涤非,赵雷,史晓飞,曹莉,哈传传.低剂量对比剂在头颈部3D CE-MRA中的应用研究[J].中国医药指南,2012,10(29):7-9. 被引量:1
-
3张格,王显龙,路世龙,黄凡衡,温志波.磁共振氨基质子转移成像在神经上皮组织肿瘤分级诊断中的应用[J].中华神经外科杂志,2013,29(10):1005-1008. 被引量:6
-
4谢玉海,范影,钱银锋,李曼曼,赵雷,史晓飞,曹莉,哈传传.小腿加压下肢动脉1.5T三维对比增强MRA对比剂剂量的对比研究[J].中国CT和MRI杂志,2014,12(6):95-98. 被引量:2
-
5石会兰,郑振峰,张云亭.钆对比剂对肾脏缺血缺氧改变的初步研究[J].临床放射学杂志,2014,33(8):1260-1264. 被引量:4
-
6徐广春,程立明,郭万首.软骨延迟增强磁共振成像在关节疾病中的应用[J].中国矫形外科杂志,2014,22(21):1974-1977. 被引量:5
-
7范影,谢玉海,李曼曼,赵雷,史晓飞,曹莉,哈传传,王军.单倍剂量三维对比增强MRA诊断脑动静脉畸形的临床价值[J].磁共振成像,2014,5(6):455-458. 被引量:7
-
8陈志章.3.0 T三维对比增强磁共振血管成像诊断糖尿病下肢动脉病变的临床应用价值[J].实用医技杂志,2015,22(5):488-489. 被引量:2
-
9刘妍姝,王海洋,景宝,李静,刘鹏飞,李露露,杨菲菲,刘景瑶.3.0T磁共振非对比剂增强触发血管成像对下肢动脉血管病变的诊断价值[J].临床和实验医学杂志,2015,14(13):1060-1062. 被引量:4
-
10于昊,王显龙,蒋山姗,冯吕金,路世龙,黄凡衡,席建东,温志波.磁共振氨基质子转移成像鉴别脑转移瘤与高级别神经上皮肿瘤的初步探讨[J].中华神经外科杂志,2015,31(10):1042-1046. 被引量:6
-
1彭佑铭,贺理宇.钆对比剂与肾源性系统性纤维化[J].临床肾脏病杂志,2011,11(7):302-304. 被引量:3
-
2谢静远,陈楠.肾源性系统纤维化[J].中华内科杂志,2008,47(7):597-599.
-
3M.R.Prince,M.Morris,J.L.MacGregor,M.E.Grossman,J.Silberzweig,苏晨.两大医疗中心肾源性系统性纤维化的发生率[J].国际医学放射学杂志,2008,31(A06):484-485. 被引量:14
-
4Neudecker B.A.,Stern R.,Mark L.A.,Steinberg S.,潘华.肾衰患者硬化性黏液水肿样皮损中含透明质酸酶:一种可能的病理生理学机制[J].世界核心医学期刊文摘(皮肤病学分册),2006,0(2):18-19.
-
5温生宝,李文方.肾源性系统性纤维化与磁共振含钆对比剂关系研究[J].现代诊断与治疗,2011,22(2):80-82. 被引量:1
-
6魏黎明,赵俊功.肾源性系统性纤维化与钆对比剂相关性探讨[J].医学研究杂志,2013,42(5):206-208. 被引量:1
-
7高华,曾新伟,李冬梅,刘艳.含钆对比剂与肾源性系统性纤维化[J].中国中西医结合影像学杂志,2011,9(3):258-261.
-
8蒋向丽.综合康复护理干预在促进颅脑外伤患者功能恢复中的应用效果观察[J].中国卫生标准管理,2015,6(23):243-244. 被引量:6
-
9丛晓毳.颅脑外伤患者行综合康复护理干预的作用[J].大家健康(学术版),2014(3):252-253. 被引量:4
-
10宣芸.含钆类造影剂诱发肾源性系统纤维化/肾源性纤维性皮肤病[J].药物不良反应杂志,2007,9(3):225-226. 被引量:1